Autism spectrum disorder (ASD) is a heterogeneous, neurodevelopmental disorder with core symptoms including deficits in social interaction, difficulties in communication, and restricted, repetitive…
Autism spectrum disorder (ASD) is a heterogeneous, neurodevelopmental disorder with core symptoms including deficits in social interaction, difficulties in communication, and restricted, repetitive…
Unipolar depression’s very crowded generic therapy market makes it a challenge for branded agents to gain a strong foothold. SSRIs’ use as first-line treatments and continued position as the…
SLE is an autoimmune condition characterized by varied symptoms and multiple organ involvement, making it a complex disease that is difficult to manage. Moreover, challenges in clinical trial…
Recent launches of trastuzumab biosimilars (Celltrion/Mundipharma’s Herzuma, Samsung Bioepis/Merck & Co.’s Ontruzant, Amgen/Allergan’s Kanjinti) have expanded the biosimilar sector of the…
MARKET OUTLOOK Progress in R&D and technology, regulatory and monetary incentives for advancing the development of treatments for rare diseases, and ongoing focus by the pharmaceutical market on…
Market Outlook The treatment armamentarium of mCRPC has significantly evolved with the addition of hormonal agents such as Zytiga (Johnson & Johnson/Janssen) and Xtandi (Medivation/Astellas …
Colorectal cancer is the third-most-common cancer globally and is associated with a five-year overall survival of 65.1%. Current treatment for metastatic colorectal cancer is dominated by…
The Parkinson’s disease (PD) market is in the midst of transformation: the first new levodopa formulation (Rytary) in over a decade launched in 2015 with more on the horizon (e.g., ND-0612, AP-…
The psoriasis therapy market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12/23…
The schizophrenia market is highly crowded given the presence of numerous antipsychotic therapies including the continued genericization of key oral therapies, the availability of newer oral…
The biosimilar/noninnovator sector of the endocrinology market is evolving. Eli Lilly/Boehringer Ingelheim’s Abasaglar/Basaglar was the first biosimilar/noninnovator insulin glargine to launch in…
MARKET OUTLOOK QUESTIONS ANSWERED What are the treatment drivers and goals for [[indication]]? What drug attributes are key influencers, which have limited impact, and which are hidden…
Market Outlook With four anti-CGRP-targeted MAbs (e.g., Amgen/Novartis’s Aimovig, Teva’s fremanezumab, Eli Lilly’s galcanezumab, and Alder’s eptinezumab) and a novel small molecule (…
The mature rheumatoid arthritis (RA) market boasts ten different biologics representing several distinct drug classes, including blockbuster tumor necrosis factor alpha (TNF-α) inhibitors Enbrel (…